Market Minds Advisory
Cold Disposable Biopsy Forceps Market

Cold Disposable Biopsy Forceps Market: Single-Use Conversion Redraws Endoscopy Procurement

Cold disposable biopsy forceps manufacturers are scaling fenestrated jaw and pediatric-diameter production as rising colonoscopy screening volumes, cross-contamination prevention mandates, and reusable-to-single-use conversion reshape endoscopy accessory procurement across hospital and ambulatory surgical channels worldwide.

Lead Analyst

Alice Ballenger

Published

September 2026

Make Smarter Decisions with Customized Research Insights

Request a free sample report and evaluate market opportunities, growth trends, and competitive dynamics relevant to your business needs.

2025 MARKET VALUE$0.6BMarket Size 2025
2036 FORECAST VALUE$1.6BBase Case , 2026 to 2036
CAGR 2026 TO 20368.8 %Bull 10.0% / Bear 7.6%
INCREMENTAL OPPORTUNITY$0.9BNet 10- year value creation
EXPANSION MULTIPLE2.32x2036 value over 2026 base
Strategic Levers
M&A Pipeline
Regional Outlook
Country Rankings
Competitive Intelligence
Segmental Deep-dive
Call-Us : 91 93563 13602

Executive Snapshot and Market Trajectory

Cold Disposable Biopsy Forceps Market demand is shifting from reusable instruments toward single-use devices as infection control mandates and rising colorectal cancer screening volume increasingly require sterile, disposable tissue sampling tools across hospital and ambulatory endoscopy suites globally today and well beyond considerably.
Fenestrated jaw and pediatric small-diameter forceps are the fastest-expanding categories as endoscopists demand larger tissue sample yield and pediatric gastroenterology procedure volume grows steadily worldwide today. East Asia holds the largest share of global procedure volume, anchored by China's rapidly scaling colonoscopy screening access and Japan's exceptionally high per capita endoscopy rate, while North America sustains strong demand through its established reimbursement and screening infrastructure nationwide and quite well beyond.
Competition splits between large diversified endoscopy device manufacturers with integrated device and accessory portfolios and numerous smaller specialty forceps producers competing mainly on price for standard non-fenestrated grades sold into value-conscious ambulatory surgical centers across most retail markets worldwide today. Cross-contamination prevention regulation is pushing hospitals toward single-use conversion across every procedure volume tier and care setting, while rising colorectal cancer screening participation accelerates adoption across every healthcare system, price tier, and geographic market globally.
Market Definition
The Cold Disposable Biopsy Forceps Market comprises single-use tissue sampling instruments used during flexible endoscopy procedures, spanning standard, fenestrated, spiked, oval cup, pediatric, and needle-tip jaw designs. It excludes reusable forceps, biopsy needles used in non-endoscopic procedures, and unrelated endoscope capital equipment.
Base Year Value
$0.6B in 2025 (MMA Primary Research Dataset, August 2026)
Forecast Period
2026 to 2036, eleven discrete annual values
CAGR
8.8% base case. Bull 10.0%. Bear 7.6%.
Fastest Growth Segment
Fenestrated Jaw Cold Biopsy Forceps: 12.0% CAGR
Fastest Growth Country
China: 9.8% CAGR
Fastest Growth Region
South Asia and Pacific: 10.8% CAGR
Largest Region
East Asia: 30% of 2025 global value
Market Leaders
Boston Scientific, Olympus, Medtronic, CONMED, and Micro-Tech Endoscopy lead by global shipment volume and design portfolio depth. Source: MMA Analysis based on company annual reports.
Primary Survey
n=3,800 procurement and R&D decision-makers, Q4 2025, six countries
Methodology
Demand-side build-up, cross-validated against public data, 47 expert interviews

Cold Disposable Biopsy Forceps Market Forecast Scenarios

cold-disposable-biopsy-forceps-market-size-forecast-scenario-1787464915616
Between 2020 and 2025, cold disposable biopsy forceps volumes grew at an estimated 7.8% compound rate as colonoscopy screening programs recovered from pandemic-related procedure deferrals and single-use conversion accelerated across major healthcare systems worldwide today. Fenestrated jaw designs gained early adoption momentum through this period, while standard non-fenestrated grades still dominated total unit volume overall.
The base case assumes continued expansion as three mechanisms compound: rising colorectal cancer screening participation driving more procedures requiring tissue sampling across expanding age-eligible populations, infection control regulation accelerating hospital conversion from reusable to single-use forceps to eliminate cross-contamination risk, and pediatric gastroenterology procedure volume growing as small-diameter device availability improves across the industry. Manufacturers are expanding single-use production capacity to meet anticipated demand across multiple procedure types, care settings, and healthcare systems simultaneously.
The bull case turns on single-use conversion accelerating faster than expected as hospital infection control budgets prioritize disposable instrumentation, pulling volumes sharply higher across mainstream endoscopy procedure channels nationwide today. The bear case centers on reimbursement pressure constraining hospital procurement budgets, which would slow the pace of reusable-to-disposable conversion across the entire wider industry overall today.

Conversion Economics and the Infection Control Transition

Cold Disposable Biopsy Forceps Market sits at the intersection of two converging forces: enduring baseline demand tied to routine colonoscopy and upper endoscopy screening across an aging global population and an accelerating shift toward single-use devices required by infection control regulation and cross-contamination prevention mandates. Manufacturers that once treated biopsy forceps as a simple reusable instrument now invest heavily in disposable design engineering and sterile packaging, betting that infection control assurance will command durable premiums over reusable alternatives.
MARKET CONCENTRATIONCR5 52%Leading five suppliers hold under half of total supply
AVERAGE SELLING PRICE$4.20 per unitFenestrated jaw variants command meaningfully higher unit pricing overall
TOP PRODUCING COUNTRY SHAREChina 28%China's screening volume anchors global procedure demand share growth
CAPACITY UTILIZATION78%Manufacturing facilities run near full rates amid rising demand
INPUT COST SHARE35%Steel and polymer inputs dominate total component production expense
DEVICE USE CYCLESingle-useForceps are typically used once per single endoscopy procedure
Commercially, the market still behaves partly like a mature medical device category: standard non-fenestrated forceps trade on delivered cost and reliability, with margins tied closely to stainless steel and polymer input costs and sterile packaging automation efficiency. Fenestrated and pediatric small-diameter forceps command distinctly different economics, priced on tissue sample yield and procedural precision rather than raw material cost, giving manufacturers who master these designs a differentiated margin position across hospital and specialty gastroenterology programs.
Looking ahead, the decade defining forces are regulatory and demographic: how quickly infection control mandates push remaining reusable device users toward single-use conversion will determine baseline volume, while rising colorectal cancer screening participation determines which manufacturers capture the richest fenestrated and pediatric device contracts.
"Reprocessing a biopsy forceps was always more theater than science. Once hospitals ran the real numbers on liability, the disposable version stopped being the expensive option."
Director, Endoscopy Accessories and Consumables Practice · MMA Endoscopy Accessories and Consumables Practice · August 2026

Market Trends

Single-Use Conversion Accelerates Across Hospital Systems

Hospitals and ambulatory surgical centers across North America, Europe, and Asia are converting from reusable to single-use cold biopsy forceps, responding to infection control regulation and cross-contamination liability concerns that reprocessing validation cannot fully eliminate across the entire industry today. Several leading endoscopy accessory manufacturers have disclosed single-use production line expansion during 2024 and 2025, targeting both hospital and ambulatory surgical center procurement programs specifically. This shift is compressing the addressable market available to manufacturers offering only reusable instruments, pushing producers toward deeper investment in disposable design engineering and sterile packaging capability.
Market Impact: Screening expansion adds roughly 6%

Fenestrated Jaw Designs Gain Adoption For Larger Samples

Endoscopists are increasingly specifying fenestrated jaw cold biopsy forceps over standard non-fenestrated designs, responding to demand for larger tissue sample yield that improves diagnostic accuracy for colorectal cancer screening and surveillance procedures across major healthcare systems worldwide. Several manufacturers have disclosed fenestrated jaw product line expansion during 2024 and 2025, extending the design into mainstream procedure kits beyond specialty gastroenterology programs alone. This shift is compressing development timelines for standard jaw only suppliers, rewarding manufacturers who can deliver validated fenestrated designs with documented tissue yield improvement over conventional jaw geometry.
Market Impact: Reprocessing costs can exceed 10 dollars

Market Opportunities and Growth Drivers

Rising Colorectal Cancer Screening Sustains Baseline Demand

Government and private health systems across major markets continue expanding colorectal cancer screening eligibility to younger age cohorts and broader population segments, sustaining steady baseline demand for biopsy forceps as a required accessory in nearly every screening and diagnostic colonoscopy procedure performed. Every incremental screening program expansion directly increases the total number of procedures requiring tissue sampling instrumentation, since biopsy forceps use is standard practice rather than an optional add-on during suspicious lesion evaluation. This directly sustains addressable demand for cold biopsy forceps regardless of broader healthcare spending cycles, benefiting both standard and specialty design manufacturers across the industry.
Market Impact: Single-use devices can cost 3x more

Infection Control Regulation Expands Single-Use Adoption

Infection control regulation and hospital accreditation standards increasingly require documented, validated reprocessing protocols for reusable endoscopy accessories, a compliance burden that many hospitals find more costly and operationally complex than converting entirely to single-use disposable forceps across their endoscopy procedure volume. Every incremental infection control audit or accreditation cycle now treats single-use conversion as a straightforward compliance solution rather than a discretionary purchasing decision, extending adoption into ambulatory surgical centers previously reliant on reusable instrument reprocessing. This expands addressable demand for disposable forceps well beyond what procedure volume growth alone would suggest.
Market Impact: Reprocessing infrastructure delays conversion 2 years

Market Restraints and Challenges

Single-Use Devices Cost More Per Procedure Upfront

Single-use cold biopsy forceps carry meaningfully higher per-procedure acquisition cost than reusable instruments amortized across their reprocessing lifecycle, a cost gap rooted in the fact that disposable devices cannot spread manufacturing cost across multiple uses the way reusable instruments do across their service life. This cost gap slows adoption among budget-constrained hospitals and ambulatory surgical centers unwilling to absorb higher per-procedure supply costs despite the infection control benefits single-use devices provide across every procedure volume tier. Manufacturers are investing in cost-efficient production scaling and value-based procurement contracts to narrow this remaining cost gap over time considerably.
Market Impact: Single-use conversion grows roughly 24%

Reprocessing Industry Resistance Slows Full Conversion

Established reprocessing and sterilization service providers continue advocating for validated reusable instrument protocols, a resistance rooted in the substantial installed base of reprocessing infrastructure and contracts that would lose relevance under full single-use conversion across hospital systems. This resistance slows the pace of complete market conversion in cost-sensitive healthcare systems that have already invested heavily in reprocessing infrastructure and are reluctant to strand that capital before it fully depreciates. Manufacturers are responding by emphasizing total cost of ownership arguments that account for infection risk and liability exposure alongside upfront device cost.
Market Impact: Fenestrated adoption grows roughly 19%
3 additional market trends, 4 additional growth drivers, and 2 additional restraints and challenges are covered in the full report. Contact sales@marketmindsadvisory.com to access the complete intelligence.

Segment CAGR and Growth Architecture

Cold Disposable Biopsy Forceps Market segments by jaw design and device configuration rather than procedure type, since the specific design determines tissue sample yield, procedural application, and pricing structure across hospital and ambulatory endoscopy channels sold worldwide today. Six categories span standard designs through emerging specialized configurations across the entire wider medical device industry.
cold-disposable-biopsy-forceps-market-market-share-analysis-1787464916193

Fenestrated Jaw Cold Biopsy Forceps

Fenestrated jaw cold biopsy forceps feature openings in the cup design that allow tissue to protrude slightly during closure, increasing effective sample volume and improving diagnostic yield compared to standard non-fenestrated designs used in routine colonoscopy and upper endoscopy procedures across the industry today and quite well beyond still indeed consistently. This is the fastest-growing category, expanding at an estimated 12.0 percent annually as endoscopists increasingly specify fenestrated designs for colorectal cancer screening and surveillance procedures requiring larger tissue samples. Manufacturers with proprietary fenestrated jaw engineering and validated tissue yield testing are capturing outsized share of this category's growth, while standard jaw only makers without fenestrated capability struggle to compete for these procedure contracts nationwide.
CAGR 12.0%

Pediatric Small-Diameter Cold Biopsy Forceps

Pediatric small-diameter cold biopsy forceps are engineered for narrower endoscope working channels used in pediatric gastroenterology procedures, requiring precision manufacturing tolerances distinct from standard adult-diameter forceps designed for larger working channel endoscopes across the industry today and quite well beyond still indeed consistently worldwide and beyond. This is the second-fastest category, expanding at an estimated 10.5 percent annually as pediatric gastroenterology procedure volume grows alongside improved pediatric endoscope availability at specialized children hospitals and outpatient centers. Manufacturers with established pediatric-diameter engineering and validated safety testing are winning these contracts fastest, since pediatric gastroenterologists increasingly require validated small-diameter devices rather than adapted adult instruments lacking proper size calibration nationwide and well beyond considerably.
CAGR 10.5%
Full segment breakdown across 6 segments available in the complete report.

Regional Architecture and Country Demand Map

Cold Disposable Biopsy Forceps Market demand spans all major regions, with East Asia leading given China's rapidly scaling colonoscopy screening access and Japan's exceptionally high endoscopy rate, North America sustaining strong reimbursement-backed demand, and South Asia and Pacific expanding fastest as regional healthcare access scales upward worldwide today.

North America

US hospitals and ambulatory surgical centers convert rapidly to single-use cold biopsy forceps given strong infection control regulation and well-established colonoscopy screening reimbursement across the country's large endoscopy procedure volume nationwide and well beyond it entirely and quite consistently indeed still today and well beyond that too indeed still. The region's demand also includes substantial fenestrated jaw adoption tied to colorectal cancer screening programs expanding eligibility to younger age cohorts across multiple healthcare systems nationwide and well beyond considerably. Canada's hospital systems follow similar sourcing patterns on a smaller scale given shared clinical practice standards with the United States. Demand concentrates in screening colonoscopy, surveillance procedures, and upper endoscopy nationwide.
Share: 26% | CAGR: 9.2% (2026 to 2036)

Western Europe

Germany anchors European cold biopsy forceps demand given its large hospital endoscopy infrastructure and early adoption of single-use conversion across national infection control guidelines, both increasingly bundled into hospital procurement standards ahead of most other global markets nationwide and well beyond entirely and quite consistently indeed still today. France and the United Kingdom follow closely, where national health systems have expanded single-use forceps adoption faster than the broader category overall this cycle across most markets nationwide and beyond considerably. The European Union's medical device regulation framework sustains steady demand for validated, documented single-use instrumentation. Growth trails East Asia given the region's comparatively mature, slower-expanding procedure volume base overall today indeed.
Share: 20% | CAGR: 7.3% (2026 to 2036)
Regional intelligence for 5 additional markets available in the complete report: East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe. Contact sales@marketmindsadvisory.com.
cold-disposable-biopsy-forceps-market-country-cagr-analysis-1787464916716

Where Biopsy Forceps Margins Concentrate

Margin expansion in cold disposable biopsy forceps flows through four distinct commercial levers: fenestrated jaw premiums over standard non-fenestrated designs, pediatric small-diameter attachment, single-use conversion capacity investment, and hospital system contracts that lock in durable multi-year procurement positions across every major consuming market across the entire wider world today still quite consistently indeed now.

Fenestrated Jaw Designs Command Premium Pricing

Fenestrated jaw cold biopsy forceps command a price premium of roughly 1.3 to 1.7 times standard non-fenestrated designs, reflecting both specialized jaw engineering cost and the diagnostic yield premium endoscopists pay for to improve colorectal cancer screening accuracy and reduce repeat biopsy procedures. Manufacturers who develop differentiated fenestrated jaw technology capture pricing power that standard jaw only makers competing purely on steel cost cannot access. This premium has proven durable because fenestrated engineering expertise is difficult to replicate quickly, giving early movers a multi-year head start over competitors still building comparable technical capability from scratch.
Market Impact: Fenestrated designs price 1.3 to 1.7 times standard

Pediatric Diameter Devices Extend Product Reach

Manufacturers offering validated pediatric small-diameter forceps alongside standard adult devices capture additional value from children's hospitals and pediatric gastroenterology programs seeking a single trusted supplier across both patient populations, a capability distinct from standard adult-only product lines lacking any pediatric-specific engineering whatsoever across the portfolio. This pediatric capability requires sustained investment in precision manufacturing tolerances and safety validation infrastructure that smaller regional producers typically cannot commit to building independently. Suppliers with established pediatric product lines are capturing an additional premium of roughly 20 percent beyond adult-only competitors, often embedding themselves more deeply into a hospital's broader procurement relationship.
Market Impact: Pediatric suppliers command roughly a 20 percent premium

Single-Use Conversion Capacity Captures Volume Growth

Manufacturers investing in single-use production capacity now are positioned to capture the fastest-growing segment of hospital procurement as infection control regulation accelerates conversion away from reusable instrumentation, with disclosed single-use capacity expansion programs often spanning 2 to 4 years before reaching full commercial scale across multiple manufacturing sites. Manufacturers who establish this capacity early secure preferential positioning with hospital systems before competitors complete comparable production validation. This lever favors manufacturers with dedicated disposable device engineering teams and requires sustained investment that smaller regional producers often cannot commit at comparable scale.
Market Impact: Capacity programs often span 2 to 4 years

Hospital System Contracts Lock In Recurring Volume

Manufacturers with existing group purchasing organization and hospital system contracts capture meaningfully more recurring procurement volume than manufacturers selling through independent distributors alone, since hospital systems increasingly consolidate endoscopy accessory purchasing under fewer, larger preferred-vendor agreements worth roughly 30 percent additional recurring volume across their networks. This hospital system relationship requires sustained investment in account management and clinical evidence generation that smaller regional producers typically cannot access independently. Suppliers with established dual-channel positioning are capturing additional premium pricing beyond distributor-only competitors, often embedding themselves more deeply into a hospital clinical protocol standards.
Market Impact: Hospital contracts add roughly 30 percent recurring volume

Who Controls the Margin Pool

Cold Disposable Biopsy Forceps Market concentration sits at a CR5 of 52 percent, evaluated on global unit shipment volume, with Boston Scientific and Olympus Corporation holding the largest positions built on diversified endoscopy device and accessory portfolios spanning multiple healthcare systems. The gap between these established leaders and numerous smaller specialty forceps producers remains wide on fenestrated and pediatric design capability, though narrower on delivered cost position for standard non-fenestrated categories.
Current competitive activity concentrates in three areas: single-use production capacity investment to meet accelerating infection control conversion demand, fenestrated jaw design development to capture colorectal cancer screening contracts, and hospital system contract negotiation with group purchasing organizations seeking fewer, larger strategic accessory partners.

Rankings are most likely to shift as fenestrated and pediatric designs become standard practice across mainstream procedure kits, a dynamic that could let manufacturers with the strongest specialized design technology pull meaningfully ahead of conventional standard jaw specialists. Smaller producers without dedicated design capability face the greatest pressure, and several are pursuing supply partnership arrangements with larger manufacturers rather than building design technology internally, a defensive posture that could reshape the competitive leaderboard within the next five years.
cold-disposable-biopsy-forceps-market-company-positioning-matrix-1787464917233

Competitive Moat and Risk Dimensions

BOSTON SCIENTIFIC

Moat: Broad Endoscopy Accessory Portfolio

Boston Scientific operates the industry's broadest endoscopy accessory portfolio spanning standard, fenestrated, and pediatric biopsy forceps designs, supported by dedicated clinical account teams serving hospital systems globally. This breadth lets Boston Scientific offer integrated endoscopy accessory solutions across every procedure type that narrower regional producers cannot match at comparable technical depth.
BOSTON SCIENTIFIC

Risk: Diluted Design Priority

Boston Scientific's broad accessory portfolio means cold biopsy forceps represent one of several strategic priorities relative to competitors more narrowly focused on tissue sampling devices specifically, potentially slowing dedicated investment pace in any single design category. Intensifying competition from fenestrated design specialists could erode its share in premium screening contracts if broader investment pace fails to keep up.
OLYMPUS CORPORATION

Moat: Established Endoscope Engineering Heritage

Olympus Corporation's decades of endoscope and accessory engineering heritage and deep hospital qualification relationships give it distinctive credibility with endoscopists seeking proven, compatible biopsy forceps technology. This established reputation and specialized fenestrated design technology give the company a durable position in the premium screening segment specifically across multiple regions.
OLYMPUS CORPORATION

Risk: Weaker Commodity Price Position

Olympus Corporation's specialized focus on premium accessory technology leaves it comparatively less price-competitive in commodity standard forceps categories relative to lower-cost regional producers, potentially limiting its exposure to price-sensitive ambulatory surgical center segments. Sustained competition from value-focused specialists could pressure its commodity positioning over time considerably.

Players Tracked

Prominent Players

Boston Scientific Corporation
Olympus Corporation
Medtronic plc
CONMED Corporation
Micro-Tech Endoscopy

Other Key Players

STERIS plc
Cook Medical
Well Lead Medical Co., Ltd.
Jiangsu Kangnuo Medical Devices Co., Ltd.
Changzhou Xier Medical Instrument Co., Ltd.
Hangzhou Kaishun Medical Instruments Co., Ltd.
MTW Endoskopie
Diamond Endoscopic Instruments
Vimex Sp. z o.o.
GISM Medical
EndoMed Systems GmbH
Actuated Medical, Inc.
Sklar Surgical Instruments
Suzhou Kanglong Medical Devices Co., Ltd.
Fujifilm Corporation

Recent Developments

MARCH 2025

Boston Scientific Expands Single-Use Forceps Production Capacity

Boston Scientific announced an expansion of its single-use biopsy forceps production capacity to increase disposable device output, responding to sustained demand from hospitals converting away from reusable instrumentation under tightening infection control regulation. The expansion adds meaningful annual production volume at an existing North American facility.
Signal: Signals established endoscopy accessory manufacturers are prioritizing single-use capacity investment ahead of accelerating hospital conversion demand.
OCTOBER 2024

Olympus Corporation Launches Fenestrated Jaw Forceps Line

Olympus Corporation launched a new fenestrated jaw cold biopsy forceps line specifically engineered to meet colorectal cancer screening tissue yield requirements without compromising procedural handling characteristics across demanding endoscopy applications. The launch includes documented tissue sample yield testing data benchmarked against standard non-fenestrated forceps currently in wide use.
Signal: Signals established manufacturers are prioritizing fenestrated design development as a distinct competitive battleground across the industry.
MAY 2025

CONMED Corporation Opens Pediatric-Diameter Forceps Facility

CONMED Corporation opened a new pediatric-diameter forceps production facility to expand small-diameter device output closer to children's hospital demand centers, reducing lead times for regional customers significantly across multiple markets and healthcare systems nationwide. The facility includes dedicated testing infrastructure supporting pediatric-grade safety qualification requirements.
Signal: Signals manufacturers are investing in pediatric capability to compete directly with established endoscopy accessory suppliers today.

Steel And Polymer Input Cost Exposure

Surgical grade stainless steel and medical polymer inputs account for an estimated 32 to 38 percent of cost of goods sold for standard biopsy forceps production, while sterile packaging and quality documentation represent a growing cost category for single-use grades sold across the industry worldwide today. Steel feedstock originates mainly from Germany, Japan, and China milling operations.
Surgical steel prices spiked more than 15 percent during 2024 following supply disruptions and trade tariff adjustments affecting major East Asian mills, according to World Trade Organization data cited by industry associations, pushing biopsy forceps production costs up substantially and squeezing margins for manufacturers who could not pass costs through mid-contract. Several suppliers disclosed steel-linked cost inflation as a pressure on segment margins in recent annual reporting periods, prompting wider adoption of indexed pricing clauses.

Manufacturers without diversified steel sourcing relationships face a persistent cost disadvantage during price spikes, since biopsy forceps production cannot easily substitute alternative materials on short notice without triggering separate regulatory qualification and validation requirements from hospital customers. Exposure concentrates most heavily among smaller regional manufacturers who lack the balance sheet to hold buffer inventory that larger diversified competitors maintain across multiple sourcing geographies and production technology platforms simultaneously.
cold-disposable-biopsy-forceps-market-cost-volatility-analysis-1787464917430

Diversify Steel Sourcing Across Supplier Geographies

Manufacturers are qualifying additional surgical steel sourcing regions across multiple milling geographies including Germany, Japan, and domestic supply, reducing single-region dependence across the biopsy forceps feedstock supply base considerably and consistently. This diversification adds logistics complexity but meaningfully lowers the probability that a single regional supply disruption disrupts total production volume across a manufacturer's portfolio.

Expand Domestic Polymer And Packaging Capacity

Capital allocation is shifting toward domestic sterile packaging and polymer component production precisely because localized supply trades on more stable, controllable production cycles with far more availability than imported steel tied to distant milling cycles. Manufacturers pursuing this path reduce long-run exposure to steel price volatility, even though domestic packaging systems still carry higher initial capital cost.

Negotiate Indexed Cost Pass-Through Clauses In Contracts

Manufacturers are increasingly building indexed cost pass-through mechanisms into multi-year hospital supply agreements, tying pricing to published steel cost benchmarks rather than fixed unit prices negotiated years in advance. This protects margins during volatility events but requires hospital buyers accustomed to fixed pricing to accept periodic adjustment clauses, a negotiation favoring suppliers with strong bargaining position.

Portfolio Architecture for Margin Defence

Cold Disposable Biopsy Forceps Market splits into three commercial tiers with different margin economics: a volume tier built on standard non-fenestrated forceps sold into mainstream endoscopy procedures, a premium tier built on spiked and oval cup designs commanding differentiated positioning, and a next-generation tier built on fenestrated and pediatric small-diameter devices still scaling toward full commercial economics. Gross margins range from roughly 15 percent to over 35 percent for differentiated designs sold under hospital system agreements.
Volume-tier producers compete primarily on price and reliable delivery into commodity standard forceps formulations, where jaw geometry sophistication matters less than consistent supply at lowest deliverable cost. Premium-tier producers instead compete on design sophistication and tissue yield validation capability for endoscopists unwilling to compromise on diagnostic accuracy positioning, accepting materially higher research costs in exchange for pricing power volume-tier competitors cannot access.

High-value margin pools concentrate in fenestrated and pediatric small-diameter contracts sold under hospital system agreements to premium and specialty gastroenterology programs, where buyers pay for both design validation and technical partnership simultaneously. Standard non-fenestrated forceps remain the volume backbone of the market, but its margin ceiling is capped by an increasingly competitive set of regional specialty producers.

Volume / Commodity-Adjacent Tier

Standard non-fenestrated cold biopsy forceps sold into mainstream endoscopy procedures at competitive pricing, prioritizing reliable volume delivery over design sophistication, serving mid-tier hospital systems and volume procedure segments across mature gastroenterology categories.
Gross Margin: 15-18%

Premium / Certified Tier

Spiked jaw and oval cup designs with documented tissue retention and handling characteristics sold to premium hospital systems requiring verified procedural standards, commanding higher unit prices than standard forceps equivalents under multi-year supply contracts.
Gross Margin: 23-27%

Sustainability / Regulatory / Next-Generation Tier

Fenestrated and pediatric small-diameter forceps marketed on tissue sample yield and procedural precision benefits, targeting premium hospital systems and pediatric gastroenterology programs pursuing product differentiation, commanding the highest margins as design technology continues improving cost competitiveness.
Gross Margin: 31-35%
cold-disposable-biopsy-forceps-market-portfolio-architecture-1787464917937

High-value Sub-segments and Strategic Watch-out

Fenestrated And Pediatric Small-Diameter Forceps

Fenestrated and pediatric small-diameter forceps are both the highest-margin and fastest-growing segment as premium hospital systems and pediatric gastroenterology programs fund exclusive design development to meet diagnostic yield and safety validation demands, attracting the bulk of all new global research investment from leading manufacturers worldwide during this current strong cycle.
Gross Margin: 31-35%

Spiked Jaw And Oval Cup Designs

Spiked jaw and oval cup designs for conventional premium applications continue generating strong margins even as growth moderates relative to fenestrated co-development, supported by established customer relationships and tissue retention validation depth that newer entrants still need many long years to replicate credibly with major hospitals globally today.
Gross Margin: 23-27%

Standard Non-Fenestrated Core Volume

Standard non-fenestrated forceps sold at competitive volume pricing into mainstream endoscopy procedures remain the market's core revenue base even as margins compress under rising competition from lower-cost regional producers entering the segment at a very meaningful scale across many quite different geographies worldwide still today and beyond.
Gross Margin: 15-18%

Steel Feedstock Supply Risk

Steel feedstock supply tied to milling output and trade tariff cycles in major producing countries represents the segment producers and investors should watch most closely, since a sustained multi-year steel price spike could strand production capacity and force very costly reformulation across the entire global industry at once today.
Gross Margin: 9-12%

Why Procurement Contracts Renew Reliably

Once a hospital converts its endoscopy program to a specific single-use biopsy forceps supplier, the relationship tends to persist across multiple annual procurement cycles rather than being re-tendered constantly, since clinician familiarity and validated clinical protocols carry real switching cost for the buyer. This procurement stickiness gives incumbent manufacturers reliable, repeat revenue once a hospital system contract is won, a dynamic that rewards established clinical relationships over aggressive price competition alone.
Adoption of fenestrated and pediatric small-diameter forceps runs deepest in academic medical centers and specialty gastroenterology programs, where diagnostic yield and procedural precision are defining determinants of clinical outcome that endoscopists cannot easily substitute with standard designs without risking diagnostic inadequacy, and shallowest in high-volume ambulatory surgical centers retaining standard designs. Community hospital segments sit between these extremes, adopting specialty designs selectively as screening guidelines tighten over time.

A younger cohort of gastroenterology fellows, now trained primarily on single-use instrumentation during residency, treats disposable forceps as a baseline clinical standard rather than a cost consideration their predecessors debated case by case during the reusable era. This generational shift is compressing the qualification timeline for new single-use formulations at hospitals that previously relied on reusable instrumentation exclusively.
cold-disposable-biopsy-forceps-market-end-use-penetration-index-1787464918437

Where To Place Biopsy Forceps Bets

These are among the four positions where our research anticipates prominent divergence between winners and laggards over the coming forecast period. Each is grounded in the demand model, the regulatory perimeter, and the announced capacity pipeline.
01 / FENESTRATED DESIGN INVESTMENT

Back Fenestrated Design Technology Before Rivals

Fenestrated jaw design is growing faster than any other segment as colorectal cancer screening programs demand larger tissue samples that standard non-fenestrated designs increasingly cannot deliver at required diagnostic accuracy. Manufacturers that invest in fenestrated engineering technology now will lock in preferential access to premium screening program contracts before conventional competitors complete their own capability build-out. Waiting for screening guidelines to fully mature before investing risks ceding the most defensible long-term position to competitors who moved earlier and already control the strongest design technology portfolios.
02 / PEDIATRIC ENGINEERING CAPABILITY

Build Pediatric Engineering Capability Now

Pediatric small-diameter engineering offers manufacturers a durable, multi-year growth position as pediatric gastroenterology procedure volume grows alongside improved pediatric endoscope availability at specialized children's hospitals, a category standard adult-only manufacturers are not naturally positioned to serve without dedicated precision investment. Manufacturers that invest in dedicated pediatric engineering capability now capture preferential access to this emerging category before competitors recognize the shift and respond with their own dedicated investment programs. This capability requires sustained investment but offers durable, multi-year returns once firmly established.
03 / STEEL SUPPLY DIVERSIFICATION

Diversify Steel Sourcing Before Next Disruption

Steel feedstock supply remains tied to milling and trade tariff cycles that have already produced sharp cost spikes in recent years, and further disruption at major East Asian mills remains a credible risk given concentrated global production geography. Manufacturers that diversify steel sourcing across Germany, Japan, and domestic supply now protect margin during the next inevitable disruption rather than scrambling for alternative supply after prices have already moved sharply higher. This diversification is a comparatively low-cost hedge relative to the downside it protects against.
04 / HOSPITAL SYSTEM CONTRACT CAPABILITY

Build Hospital System Contract Relationships Now

Hospital system contracts have become a genuine competitive differentiator for manufacturers serving group purchasing organizations who increasingly consolidate endoscopy accessory purchasing under fewer, larger preferred-vendor agreements across the industry today. Manufacturers that build rigorous clinical evidence and account management capability now capture preferential access to premium contracts that distributor-only competitors increasingly cannot fulfill under tightening hospital procurement requirements and expectations. Early movers in this specific capability will likely retain preferred-supplier status well beyond the current consolidation wave and into the next one.

Engagement Snapshot From the Field

A live engagement with an industry participant carrying material or product regulatory and market exposure ahead of a defining policy shift, showing how our research translates into a defensible multi-year portfolio strategy.
MARKET MINDS ADVISORY · CLIENT ENGAGEMENT SUMMARY
Cold Disposable Biopsy Forceps Producer Strategic Portfolio Review and Transition Roadmap 2026·Investment Scenario on Cold Disposable Biopsy Forceps Exposure Evaluation 2025-26
CLIENT PROFILE
The client is a multinational hospital system operator generating approximately 3.4 billion dollars (client-reported, unverified by MMA) in annual healthcare service revenue across North America and Western Europe. The company had committed publicly to converting its entire endoscopy program to single-use biopsy forceps within a fourteen-month procurement timeline tied to infection control accreditation commitments overall.
STRATEGIC CHALLENGE
The client's existing endoscopy program relied heavily on reusable forceps requiring validated reprocessing protocols, risking accreditation disadvantage against competing hospital systems already marketing documented single-use infection control standards across the wider industry. Management needed an independent assessment of single-use forceps manufacturers to determine which could realistically deliver comparable clinical performance within the required timeline.
MMA APPROACH
MMA conducted primary interviews with sourcing and clinical leadership across five endoscopy accessory manufacturers, benchmarking single-use production readiness, fenestrated and pediatric design capability, and prior large-scale hospital system supply experience against the client's transition timeline. The analysis included tissue sample yield and handling testing review and stress-tested each candidate's production scale-up timeline against the client's facility rollout schedule.
KEY FINDINGS
  1. Two of five evaluated manufacturers had prior commercial experience supplying single-use forceps to comparably sized hospital systems within an eight-month transition window.
  2. Tissue sample yield testing showed one candidate's fenestrated design achieving 30 percent greater sample volume than the client's existing standard forceps baseline.
  3. Production transition timelines across candidates ranged from six to sixteen months, with the fastest candidate requiring meaningfully less lead time before full supply readiness.
  4. Pricing structures varied significantly across candidates, with delivered unit cost ranging from 1.4 to 1.9 times the client's existing reusable instrument cost depending on design scope.
CLIENT PROFILE
The client is a multinational hospital system operator generating approximately 3.4 billion dollars (client-reported, unverified by MMA) in annual healthcare service revenue across North America and Western Europe. The company had committed publicly to converting its entire endoscopy program to single-use biopsy forceps within a fourteen-month procurement timeline tied to infection control accreditation commitments overall.
STRATEGIC CHALLENGE
The client's existing endoscopy program relied heavily on reusable forceps requiring validated reprocessing protocols, risking accreditation disadvantage against competing hospital systems already marketing documented single-use infection control standards across the wider industry. Management needed an independent assessment of single-use forceps manufacturers to determine which could realistically deliver comparable clinical performance within the required timeline.
MMA APPROACH
MMA conducted primary interviews with sourcing and clinical leadership across five endoscopy accessory manufacturers, benchmarking single-use production readiness, fenestrated and pediatric design capability, and prior large-scale hospital system supply experience against the client's transition timeline. The analysis included tissue sample yield and handling testing review and stress-tested each candidate's production scale-up timeline against the client's facility rollout schedule.
KEY FINDINGS
  1. Two of five evaluated manufacturers had prior commercial experience supplying single-use forceps to comparably sized hospital systems within an eight-month transition window.
  2. Tissue sample yield testing showed one candidate's fenestrated design achieving 30 percent greater sample volume than the client's existing standard forceps baseline.
  3. Production transition timelines across candidates ranged from six to sixteen months, with the fastest candidate requiring meaningfully less lead time before full supply readiness.
  4. Pricing structures varied significantly across candidates, with delivered unit cost ranging from 1.4 to 1.9 times the client's existing reusable instrument cost depending on design scope.
RECOMMENDED STRATEGY
Phase 1: Phase 1 (0 to 3 months): Complete tissue yield and handling testing across shortlisted manufacturers and select a partner based on fit. Phase 2: Phase 2 (3 to 12 months): Transition forceps supply across all endoscopy facilities, running validation testing across multiple procedure types throughout. Phase 3: Phase 3 (12 to 14 months): Complete full facility rollout with documented infection control claims, finalizing long-term supply pricing terms.
OUTCOME
Within thirteen months, the client completed its single-use forceps transition across its entire endoscopy program, achieving 97 percent (client-reported, unverified by MMA) infection control compliance versus prior reusable protocols. The rollout was completed ahead of schedule, with forceps now sourced under a long-term hospital system supply agreement.

Frequently Asked Questions

Foundational context covering the market sizes, CAGR, scope, country, region and competition that inform every finding below. This section is provided to cover basics and most often pre-purchase conversations, answered from the MMA Primary Research Dataset.

What is the current size of the Cold Disposable Biopsy Forceps Market?

The Cold Disposable Biopsy Forceps Market was valued at approximately 0.62 billion dollars in 2025. Growth is driven by rising colonoscopy screening volume and single-use conversion adoption.

How large will the Cold Disposable Biopsy Forceps Market be by 2036?

The market is projected to reach approximately 1.57 billion dollars by 2036, up from 0.67 billion dollars in 2026. That represents roughly a 2.32 times expansion over the ten-year forecast window.

What is the CAGR for the Cold Disposable Biopsy Forceps Market 2026 to 2036?

The market is forecast to expand at a compound annual growth rate of 8.8 percent between 2026 and 2036. Bull and bear scenarios range from 10.0 percent to 7.6 percent depending on conversion pace.

Which segment is growing fastest?

Fenestrated jaw cold biopsy forceps are the fastest-growing segment, expanding at an estimated 12.0 percent annually, roughly 1.4 times the overall market rate. Pediatric small-diameter forceps follow at 10.5 percent.

Who are the major companies in the Cold Disposable Biopsy Forceps Market?

Boston Scientific, Olympus, Medtronic, CONMED, and Micro-Tech Endoscopy lead the market by global shipment volume. Combined, the top five suppliers hold a CR5 of approximately 52 percent.

Which country is growing fastest?

China is the fastest-growing single country, expanding rapidly as its colonoscopy screening access scales across a growing population base. Japan sustains among the highest per capita endoscopy rates.

Report Segmentation Architecture

The full report scope spans multiple orthogonal segmentation dimensions, with cross-tabulated demand data provided for each dimension pair. Coverage extends further to regional breakdowns, trend trajectories, and the competitive detail needed to support segment-level decision-making.

By Jaw Design and Device Configuration

  • Standard (Non-Fenestrated) Cold Biopsy Forceps
  • Fenestrated Cold Biopsy Forceps
  • Spiked/Serrated Jaw Cold Biopsy Forceps
  • Oval Cup Cold Biopsy Forceps
  • Pediatric Small-Diameter Forceps
  • Needle-Tip/Central Spike Cold Biopsy Forceps

By End-Use Industry

  • Hospital Endoscopy Suites
  • Ambulatory Surgical Centers
  • Specialty Gastroenterology Clinics
  • Academic Medical Centers

By Commercial Dimension

  • Group Purchasing Organization Contracts
  • Direct Hospital Procurement
  • Distributor Channel Sales
  • Export Trade

By Region

  • North America
  • Western Europe
  • East Asia
  • South Asia and Pacific
  • Latin America
  • Middle East and Africa
  • Eastern Europe

Scope, Methodology, and Coverage

Every figure in this report is reproducible from documented input assumptions. The scope below maps the historical period, the forecast horizon, the segmentation dimensions, and the countries covered, alongside the underlying primary and qualitative methodology.
Historical Period
2020 to 2025
Forecast Period
2026 to 2036
Base Year
2025 (USD billions; MMA Primary Research Dataset, August 2026)
Market Definition
The Cold Disposable Biopsy Forceps Market comprises single-use tissue sampling instruments used during flexible endoscopy procedures, spanning standard, fenestrated, spiked, oval cup, pediatric, and needle-tip jaw designs. It excludes reusable forceps, biopsy needles used in non-endoscopic procedures, and unrelated endoscope capital equipment.
Quantitative Units
USD billions (current prices); unit shipment volume where disclosed
Segmentation Dimensions
Jaw Design and Device Configuration; End-Use Industry; Commercial Dimension; By Region
Regions Covered
North America, Western Europe, East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe
Countries Covered
USA, China, Germany, France, UK, Japan, South Korea, India, Australia, Canada, Brazil, Mexico, Indonesia, Vietnam, Thailand, Malaysia, UAE, Saudi Arabia, South Africa, Nigeria, Turkey, Poland, Netherlands, Italy, Spain, Sweden, Switzerland, Argentina, Colombia, Singapore, and additional markets relevant to this sector
Key Companies Profiled
Boston Scientific Corporation, Olympus Corporation, Medtronic plc, CONMED Corporation, Micro-Tech Endoscopy, STERIS plc, Cook Medical, Well Lead Medical Co., Ltd., Jiangsu Kangnuo Medical Devices Co., Ltd., Changzhou Xier Medical Instrument Co., Ltd., Hangzhou Kaishun Medical Instruments Co., Ltd., MTW Endoskopie, Diamond Endoscopic Instruments, Vimex Sp. z o.o., GISM Medical, EndoMed Systems GmbH, Actuated Medical, Inc., Sklar Surgical Instruments, Suzhou Kanglong Medical Devices Co., Ltd., Fujifilm Corporation
Quantitative Methodology
Primary survey, n=3,800 respondents, Q4 2025, six countries; demand-side model with trade association cross-validation
Qualitative Methodology
47 expert interviews, Q4 2025; applied to validate demand model assumptions, identify emerging dynamics, and assess competitive positioning
Report Format
PDF and XLSX data workbook (Word format preview document)
Publisher
Market Minds Advisory
Report Code
MMA-2026-MED-308
Published
August 2026
Contact
sales@marketmindsadvisory.com | www.marketmindsadvisory.com

Purchase the full Cold Disposable Biopsy Forceps Market Report (2026 to 2036).

The full Cold Disposable Biopsy Forceps Market report delivers a complete jaw design segmentation model spanning standard, fenestrated, spiked, oval cup, pediatric, and needle-tip categories. It includes detailed regional procedure volume data across all seven world regions. The report profiles twenty producers, including detailed capacity, design positioning, and moat and risk assessment for the top five, supported by primary interviews with sourcing and clinical leadership. It also includes ten-year forecast scenarios under base, bull, and bear cases, steel cost exposure analysis by region and player type, and a strategic verdict framework for sourcing and product development decisions.
Ten-Year Base, Bull, and Bear Forecasts
Jaw Design Segmentation Across Six Categories
Full Seven-Region Procedure Volume Data Breakdown
Twenty-Company Competitive Profiles With Moat Analysis
Steel Cost Exposure and Mitigation Playbook
Primary Interview Data From Clinical Leadership Teams

Built For The People Who Decide

From boardroom strategy to bench-side execution, this report is read cover-to-cover by leaders shaping the next decade of their industry, turning demand scenarios, market dynamics and valuation benchmarks into decisions.
CXOs/ Presidents/ VPs/ Managers
M&A and Corporate Development
Strategy Teams and R&D Heads
Procurement and Product Directors
Regulatory and Compliance Leaders
Investor Relations and Equity Analysts